August 2025 in “JAAD International” Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
2 citations
,
November 1990 in “International Journal of Dermatology” Albendazole can cause hair loss, and piroxicam can cause fixed drug eruption.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
16 citations
,
November 2023 in “Scientific Reports” The niosomes effectively target hair follicles for acne treatment.
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
January 2005 in “Fuzhou daxue xuebao. Ziran kexue ban” The method is quick and effective for testing steroid 5 alpha-reductase inhibitors.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
6 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.
November 2005 in “Reactions Weekly” A man treated with gefitinib for lung cancer grew new hair on his bald scalp.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
Acitretin improved monilethrix symptoms temporarily, but they returned after stopping treatment.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
January 2025 in “JCEM Case Reports” Ketoconazole improved symptoms of ACTH-independent Cushing syndrome despite inconclusive initial scans.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
January 2022 in “eJournal Kedokteran Indonesia” Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
1 citations
,
May 2021 in “Journal of the Endocrine Society” A woman developed Cushing syndrome and adrenal insufficiency from using fluticasone and ritonavir together.
December 2012 in “http://isrctn.org/>”
7 citations
,
December 2013 in “The Journal of Dermatology” A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
April 2011 in “Reactions Weekly” 3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.